Literature DB >> 14657948

Extraskeletal myxoid chondrosarcomas do not show a chondrocytic phenotype.

Thomas Aigner1, André M Oliveira, Antonio G Nascimento.   

Abstract

Extraskeletal myxoid chondrosarcoma is a rare mesenchymal soft-tissue malignancy of putative chondrocytic differentiation. Occasional overt cartilage formation, positivity for S-100 protein, and ultrastructural analysis have supported this view. However, most extraskeletal myxoid chondrosarcomas do not show chondroid tissue formation, and S-100 protein is found much less commonly than has been reported. Both these observations cast doubt on the histogenetic classification of extraskeletal myxoid chondrosarcoma as a chondroblastic entity. Mostly using matrix proteins as markers of mesenchymal cell differentiation, we investigated the biochemical matrix composition and cellular phenotype of the tumor cells in representative specimens from 14 extraskeletal myxoid chondrosarcomas. In all but one tumor specimen, which showed histomorphologically overt cartilage formation, only occasional staining for the proteoglycan aggrecan was found. Specimens from two tumors showed presence of collagen type II, and none was positive for collagen type X. Instead, collagen types I, III, and VI were diffusely positive. Also, S-100 protein was largely absent. Our results suggest that the basic cellular phenotype of extraskeletal myxoid chondrosarcoma is not chondrocytic or prechondrocytic and that extraskeletal myxoid chondrosarcoma is not a chondrosarcomatous entity. Extraskeletal myxoid chondrosarcoma consists most likely of primitive mesenchymal cells with focal, multidirectional differentiation. Chondrocytic differentiation is an unusual facet in the spectrum of differentiation patterns exhibited by these lesions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14657948     DOI: 10.1038/modpathol.3800036

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  16 in total

1.  Identification of genes regulated by the EWS/NR4A3 fusion protein in extraskeletal myxoid chondrosarcoma.

Authors:  Christine Filion; Yves Labelle
Journal:  Tumour Biol       Date:  2012-05-18

2.  Extraskeletal myxoid chondrosarcoma of the heart and review of current literature.

Authors:  H L Geyer; N Karlin
Journal:  Curr Oncol       Date:  2010-10       Impact factor: 3.677

3.  Distinguishing chordoid meningiomas from their histologic mimics: an immunohistochemical evaluation.

Authors:  Ankur R Sangoi; Mohanpal S Dulai; Andrew H Beck; Daniel J Brat; Hannes Vogel
Journal:  Am J Surg Pathol       Date:  2009-05       Impact factor: 6.394

4.  Extraskeletal Myxoid Chondrosarcoma of the Orbit.

Authors:  Abdullah M Al-Osaily; Faisal N Al-Dosari; Mostaf A Elewa; Sohail A Butt
Journal:  Middle East Afr J Ophthalmol       Date:  2016 Apr-Jun

5.  INSM1 expression and its diagnostic significance in extraskeletal myxoid chondrosarcoma.

Authors:  Akihiko Yoshida; Naohiro Makise; Susumu Wakai; Akira Kawai; Nobuyoshi Hiraoka
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

6.  Reticular schwannoma mimicking myxoid sarcoma.

Authors:  Jai Kumar Chaurasia; Nishat Afroz; Biswajit Sahoo; Mohammed Naim
Journal:  BMJ Case Rep       Date:  2014-02-20

7.  Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy.

Authors:  Alex D Drilon; Sanjay Popat; Gauri Bhuchar; David R D'Adamo; Mary Louise Keohan; Cyril Fisher; Cristina R Antonescu; Samuel Singer; Murray F Brennan; Ian Judson; Robert G Maki
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

Review 8.  Running GAGs: myxoid matrix in tumor pathology revisited: what's in it for the pathologist?

Authors:  Stefan M Willems; Malgorzata Wiweger; J Frans Graadt van Roggen; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2009-08-25       Impact factor: 4.064

Review 9.  Soft tissue tumors associated with EWSR1 translocation.

Authors:  Salvatore Romeo; Angelo P Dei Tos
Journal:  Virchows Arch       Date:  2010-02       Impact factor: 4.064

10.  NFATc2-rearranged sarcomas: clinicopathologic, molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker.

Authors:  Raul Perret; Julien Escuriol; Valérie Velasco; Laetitia Mayeur; Isabelle Soubeyran; Christophe Delfour; Sébastien Aubert; Marc Polivka; Marie Karanian; Alexandra Meurgey; Sophie Le Guellec; Noelle Weingertner; Sylvia Hoeller; Jean-Michel Coindre; Frédérique Larousserie; Gaëlle Pierron; Franck Tirode; François Le Loarer
Journal:  Mod Pathol       Date:  2020-04-23       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.